StimCardio raises $30.0M Series A (United States, Oct 2026)
Reach the investors backing rounds like this
Backed by John Slump's family office, Metis Medtech, Catalyst Health Ventures · verified emails and LinkedIn on Datapile
StimCardio Closes Oversubscribed $30 Million Series A Financing to Advance Wearable Therapeutic for Atrial Fibrillation - BioSpace
StimCardio is a clinical-stage medical device company developing non-invasive wearable therapeutics for atrial fibrillation (AF). Their lead product, Rhyvive, is designed to extend AF treatment beyond the hospital and into the home, targeting a significant unmet clinical need in cardiac electrophysiology.
StimCardio Closes Oversubscribed $30 Million Series A Financing to Advance Wearable Therapeutic for Atrial Fibrillation BioSpace
| Oct 30, 2026 | Rune Technologies | $375.0M | — | United States |
| Oct 30, 2026 | Pluto Aerospace | $2.5M | Seed | United States |
| Oct 30, 2026 | Audio Chateau Records | $9.0M | Series A | United States |
| Oct 30, 2026 | AvalonX | $10.0M | — | United States |
22,420 investors back startups in United States
You just read who funded StimCardio. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.